We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+11.85%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.51B
AUM Growth
-$26.5M
Cap. Flow
-$152M
Cap. Flow %
-10.08%
Top 10 Hldgs %
28.6%
Holding
136
New
8
Increased
26
Reduced
33
Closed
15

Top Buys

Rank Stock Value
1
TWLO icon
Twilio
TWLO
+$20.1M
2
W icon
Wayfair
W
+$13.8M
3
VMC icon
Vulcan Materials
VMC
+$13.5M
4
AIMT
Aimmune Therapeutics
AIMT
+$6.36M
5
XLRN
Acceleron Pharma
XLRN
+$5.93M

Top Sells

Rank Stock Value
1
MBLY
Mobileye N.V.
MBLY
+$33.3M
2
LEA icon
Lear
LEA
+$23.6M
3
ABBV icon
AbbVie
ABBV
+$17.9M
4
ATHN
Athenahealth, Inc.
ATHN
+$17.5M
5
BWA icon
BorgWarner
BWA
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 33.11%
2 Consumer Discretionary 15.23%
3 Technology 14.9%
4 Industrials 11.42%
5 Utilities 4.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
76
Aclaris Therapeutics
ACRS
$743M
$4.17M 0.28%
140,000
-80,000
-36% -$2.31M
TSRO
77
DELISTED
TESARO, Inc.
TSRO
$4M 0.26%
26,000
-39,000
-60% -$6.35M
VYGR icon
78
Voyager Therapeutics
VYGR
$189M
$3.97M 0.26%
300,000
– –
RGEN icon
79
Repligen
RGEN
$7.03B
$3.87M 0.26%
110,000
– –
BOLD
80
DELISTED
Audentes Therapeutics, Inc
BOLD
$3.83M 0.25%
225,000
– –
VRTX icon
81
Vertex Pharmaceuticals
VRTX
$122B
$3.78M 0.25%
34,600
– –
MYOV
82
DELISTED
Myovant Sciences Ltd.
MYOV
$3.46M 0.23%
+295,000
New +$3.38M
ATRC icon
83
AtriCure
ATRC
$2.04B
$3.45M 0.23%
180,000
– –
TCON
84
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$3.38M 0.22%
4,500
+172
+4% +$154K
CHRS icon
85
Coherus Oncology
CHRS
$227M
$3.07M 0.2%
145,000
– –
NTUS
86
DELISTED
Natus Medical Inc
NTUS
$2.94M 0.19%
75,000
– –
NGNE icon
87
Neurogene
NGNE
$670M
$2.92M 0.19%
8,750
– –
MGNX icon
88
MacroGenics
MGNX
$240M
$2.73M 0.18%
147,000
-578,800
-80% -$11.2M
CTMX icon
89
CytomX Therapeutics
CTMX
$714M
$2.59M 0.17%
150,000
– –
ACHN
90
DELISTED
Achillion Pharmaceuticals
ACHN
$2.53M 0.17%
+600,000
New +$2.49M
SYRS
91
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.39M 0.16%
15,000
– –
CDTX
92
DELISTED
Cidara Therapeutics
CDTX
$2.06M 0.14%
13,200
– –
JUNO
93
DELISTED
Juno Therapeutics, Inc.
JUNO
$2M 0.13%
90,000
– –
SEP
94
DELISTED
Spectra Engy Parters Lp
SEP
$1.66M 0.11%
38,000
+3,000
+9% +$134K
ALDR
95
DELISTED
Alder Biopharmaceuticals
ALDR
$1.64M 0.11%
79,000
-136,000
-63% -$3.01M
BLCM
96
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.6M 0.11%
13,000
-12,000
-48% -$1.57M
TIG
97
DELISTED
TiGenix American Depositary Shares
TIG
$1.56M 0.1%
100,000
– –
HTGC icon
98
Hercules Capital
HTGC
$2.98B
$1.51M 0.1%
100,000
-6,000
-6% -$88K
ARAY icon
99
Accuray
ARAY
$33.9M
$1.45M 0.1%
306,200
– –
TSM icon
100
TSMC
TSM
$2.09T
$1.41M 0.09%
43,000
+4,500
+12% +$141K
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Eventide Asset Management held 136 positions worth $1.51B, down 1.7% from $1.54B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Eventide Asset Management withdrew a net $152M in Q1 2017, closing 15 positions and reducing 33 holdings. Its most notable exit was Mobileye N.V., an estimated $33.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Eventide Asset Management opened a new position in Twilio worth $19.2M.

  • Eventide Asset Management's largest Q1 2017 buy was Twilio: 665,000 shares worth $19.2M.
  • Eventide Asset Management added most to Wayfair in Q1 2017, an estimated $13.8M increase.
  • Eventide Asset Management's biggest Q1 2017 reduction was Lear, cutting an estimated $23.6M.
  • Eventide Asset Management fully exited Mobileye N.V. in Q1 2017, selling an estimated $33.3M.
  • Eventide Asset Management's ten largest holdings make up 29% of its $1.51B portfolio in Q1 2017.
  • Eventide Asset Management opened 8 new positions and closed 15 in Q1 2017.
  • Eventide Asset Management's portfolio value fell 1.7% quarter-over-quarter to $1.51B.

Based on Eventide Asset Management's 13F filing for Q1 2017, filed 15 May 2017.